JD 005
Alternative Names: JD-005Latest Information Update: 11 Nov 2022
At a glance
- Originator Beijing JD Biotech
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Gastric cancer
Most Recent Events
- 18 Oct 2022 Early research in Gastric cancer in China (Parenteral) (Beijing JD Biotech pipeline, October 2022)